智通财经APP获悉，宜明昂科-B(01541)高开逾3%，截至发稿，涨3.7%，报4.77港元，成交额38.73万港元。
消息面上，宜明昂科-B发布公告，IMM2510联合化疗进行非小细胞肺癌(NSCLC)一线治疗的Ib/II期临床试验成功完成首例患者给药。安全性导入期后，公司计划在上述临床试验中招募一线患者，预计最早于2025年下半年发布初步临床数据，包括来自NSCLC一线患者的数据。
据介绍，IMM2510I期剂量递增研究的临床数据显示出令人鼓舞的疗效迹象：数名曾接受多种疗法失败的晚期实体瘤患者在接受IMM2510治疗后达到部分缓解(PR)。截至2024年12月31日，招募超过100名患者加入IMM2510单药治疗的I/II期临床试验。在多种实体瘤适应症(包括NSCLC、三阴性乳腺癌(TNBC)及软组织肉瘤(STS)等重复治疗失败的患者)中观察到良好的耐受性及有前景的初步PR信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.